Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

77 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Emicizumab for the treatment of acquired hemophilia A.
Knoebl P, Thaler J, Jilma P, Quehenberger P, Gleixner K, Sperr WR. Knoebl P, et al. Among authors: gleixner k. Blood. 2021 Jan 21;137(3):410-419. doi: 10.1182/blood.2020006315. Blood. 2021. PMID: 32766881 Free article.
Unique effects of KIT D816V in BaF3 cells: induction of cluster formation, histamine synthesis, and early mast cell differentiation antigens.
Mayerhofer M, Gleixner KV, Hoelbl A, Florian S, Hoermann G, Aichberger KJ, Bilban M, Esterbauer H, Krauth MT, Sperr WR, Longley JB, Kralovics R, Moriggl R, Zappulla J, Liblau RS, Schwarzinger I, Sexl V, Sillaber C, Valent P. Mayerhofer M, et al. J Immunol. 2008 Apr 15;180(8):5466-76. doi: 10.4049/jimmunol.180.8.5466. J Immunol. 2008. PMID: 18390729 Free PMC article.
High STAT5 levels mediate imatinib resistance and indicate disease progression in chronic myeloid leukemia.
Warsch W, Kollmann K, Eckelhart E, Fajmann S, Cerny-Reiterer S, Hölbl A, Gleixner KV, Dworzak M, Mayerhofer M, Hoermann G, Herrmann H, Sillaber C, Egger G, Valent P, Moriggl R, Sexl V. Warsch W, et al. Among authors: gleixner kv. Blood. 2011 Mar 24;117(12):3409-20. doi: 10.1182/blood-2009-10-248211. Epub 2011 Jan 10. Blood. 2011. PMID: 21220747 Free article.
CD34(+)/CD38(-) stem cells in chronic myeloid leukemia express Siglec-3 (CD33) and are responsive to the CD33-targeting drug gemtuzumab/ozogamicin.
Herrmann H, Cerny-Reiterer S, Gleixner KV, Blatt K, Herndlhofer S, Rabitsch W, Jäger E, Mitterbauer-Hohendanner G, Streubel B, Selzer E, Schwarzinger I, Sperr WR, Valent P. Herrmann H, et al. Among authors: gleixner kv. Haematologica. 2012 Feb;97(2):219-26. doi: 10.3324/haematol.2010.035006. Epub 2011 Oct 11. Haematologica. 2012. PMID: 21993666 Free PMC article.
The Hsp32 inhibitors SMA-ZnPP and PEG-ZnPP exert major growth-inhibitory effects on D34+/CD38+ and CD34+/CD38- AML progenitor cells.
Herrmann H, Kneidinger M, Cerny-Reiterer S, Rülicke T, Willmann M, Gleixner KV, Blatt K, Hörmann G, Peter B, Samorapoompichit P, Pickl W, Bharate GY, Mayerhofer M, Sperr WR, Maeda H, Valent P. Herrmann H, et al. Among authors: gleixner kv. Curr Cancer Drug Targets. 2012 Jan;12(1):51-63. doi: 10.2174/156800912798888992. Curr Cancer Drug Targets. 2012. PMID: 22165967
European Competence Network on Mastocytosis (ECNM): 10-year jubilee, update, and future perspectives.
Valent P, Arock M, Bonadonna P, Brockow K, Broesby-Olsen S, Escribano L, Gleixner KV, Grattan C, Hadzijusufovic E, Hägglund H, Hermine O, Horny HP, Kluin-Nelemans HC, Maurer M, Niedoszytko M, Nedoszytko B, Nilsson G, Oude-Elberink HN, Orfao A, Radia D, Reiter A, Siebenhaar F, Sotlar K, Sperr WR, Triggiani M, VanDoormaal JJ, Várkonyi J, Yavuz S, Hartmann K. Valent P, et al. Among authors: gleixner kv. Wien Klin Wochenschr. 2012 Dec;124(23-24):807-14. doi: 10.1007/s00508-012-0293-z. Epub 2012 Nov 20. Wien Klin Wochenschr. 2012. PMID: 23179435 Review.
77 results